Terms: = Head and neck cancer AND MAP2K2, MEK2, 5605, ENSG00000126934, P36507, MKK2, MAPKK2, PRKMK2 AND Treatment
5 results:
1. Daurisoline suppresses esophageal squamous cell carcinoma growth in vitro and in vivo by targeting MEK1/2 kinase.
Wang D; Zhang W; Zhang X; Li M; Wu Q; Li X; Zhao L; Yuan Q; Yu Y; Lu J; Zhao J; Dong Z; Liu K; Jiang Y
Mol Carcinog; 2023 Apr; 62(4):517-531. PubMed ID: 36645220
[TBL] [Abstract] [Full Text] [Related]
2. Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveals differences in efficacy and drug resistance development.
Fuse MA; Dinh CT; Vitte J; Kirkpatrick J; Mindos T; Plati SK; Young JI; Huang J; Carlstedt A; Franco MC; Brnjos K; Nagamoto J; Petrilli AM; Copik AJ; Soulakova JN; Bracho O; Yan D; Mittal R; Shen R; Telischi FF; Morrison H; Giovannini M; Liu XZ; Chang LS; Fernandez-Valle C
Neuro Oncol; 2019 Mar; 21(4):486-497. PubMed ID: 30615146
[TBL] [Abstract] [Full Text] [Related]
3. The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid cancer.
Beadnell TC; Mishall KM; Zhou Q; Riffert SM; Wuensch KE; Kessler BE; Corpuz ML; Jing X; Kim J; Wang G; Tan AC; Schweppe RE
Mol Cancer Ther; 2016 Aug; 15(8):1952-63. PubMed ID: 27222538
[TBL] [Abstract] [Full Text] [Related]
4. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
Ho AL; Grewal RK; Leboeuf R; Sherman EJ; Pfister DG; Deandreis D; Pentlow KS; Zanzonico PB; Haque S; Gavane S; Ghossein RA; Ricarte-Filho JC; DomÃnguez JM; Shen R; Tuttle RM; Larson SM; Fagin JA
N Engl J Med; 2013 Feb; 368(7):623-32. PubMed ID: 23406027
[TBL] [Abstract] [Full Text] [Related]
5. Patient time costs associated with cancer care.
Yabroff KR; Davis WW; Lamont EB; Fahey A; Topor M; Brown ML; Warren JL
J Natl Cancer Inst; 2007 Jan; 99(1):14-23. PubMed ID: 17202109
[TBL] [Abstract] [Full Text] [Related]
